Breakthrough Biotech · US & South Korea
Legend Innovation Life Science Fund invests in breakthrough biotech companies and builds scalable life-science real estate across the United States and South Korea.
Nations
United States & South Korea
Disease Targets
High-need, high-impact areas
Investment Strategies
Biotech companies & real estate
About Us
We envision a world where today's most daunting medical challenges are met with cutting-edge therapies that not only extend life but also enhance its quality. We believe that the key to unlocking this future lies in the innovative potential of biotech companies.
By providing these innovators with the resources and strategic guidance they need, we aim to transform the landscape of global healthcare. Together with our partners, we are shaping the future of medicine and paving the way for a healthier, more hopeful tomorrow.
Learn more about us →
2
Operational nations with leading life-science ecosystems
7
High-impact disease targets with transformative potential
Our Strategy
Scientific advancements, technological innovations, and societal needs are aligning to create unprecedented opportunities. Biotechnology has reached a pivotal moment for transformative therapies.
Read More →We identify and support biotech companies with the highest potential for transformative impact — with robust pipelines poised to deliver innovative therapies to the market.
Read More →A forward-thinking fund rooted in expertise, strategic alliances across the US and South Korea, and a clear path to high growth — while contributing to global health outcomes.
Read More →Leadership
SKFounder & Chairman
Yale Fellow and Seoul National University physicist whose early research shaped the active ingredients in Sensodyne. Decades of investing, real-estate, and hedge-fund experience across New York and South Korea.
Read full profile →
SKChief Financial Officer
Global financial strategist with 40+ years of experience in capital markets, investment management, and cross-border project finance.
Read full profile →
RCChief Operating Officer & Biotechnology Director
Senior operations executive with 20+ years of experience driving growth, efficiency, and transformation across life sciences, healthcare, and banking.
Read full profile →Scientific Advisory Board
Co-Founder & CEO, Accelero Biostructures
Subject matter expert in structural biology, biophysics, and AI-based drug discovery with 25 years of experience. Co-authored publications with four Nobel Laureates. Former Staff Scientist at SSRL, SLAC National Accelerator Laboratory.
CEO & Founder, Nous Biosciences
Inventor of FDA-approved TRULANCE. Guided two companies to NASDAQ listing. 35+ years in pharma/biotech with 50+ worldwide patents. Pioneer of therapeutic applications of Guanylate cyclase-C.
Distinguished Professor, Baruch S. Blumberg Institute
Co-inventor of Eliquis® (Apixaban) — currently the world's top-selling small molecule drug with ~$17B annual sales. Co-discoverer of the Chan–Lam Coupling Reaction. Recipient of the ACS Heroes of Chemistry Award.
Disease Targets
Our initial disease targets include hard to treat, high impact and high profit potential treatments.
Over 100 diseases defined by the uncontrolled growth and spread of abnormal cells.
More details →A chronic metabolic epidemic affecting 500M+ adults globally.
More details →Targeting the underlying biology of aging to extend healthy years of life.
More details →More than 80 disorders in which the immune system attacks healthy tissue.
More details →The leading cause of global mortality — including next-generation anticoagulation beyond Eliquis.
More details →The most common cause of dementia, accounting for 60–80% of cases worldwide.
More details →Progressive neurodegeneration affecting movement control and quality of life.
More details →Latest News
Legend Innovation Life Science Fund has named Accelero Biostructures a Preferred Technology Partner, giving portfolio companies access to advanced structural biology and AI-driven drug discovery platforms designed to accelerate early-stage development.
Read more →
Legend Innovation Life Science Fund and Provo Real Estate Enterprises have signed a $100 million agreement to fund healthcare innovation and develop advanced life sciences facilities in South Korea. The partnership aims to combine investment expertise and real estate development to support growth in the global healthcare technology sector.
Read more →Together with our partners, we are shaping the future of medicine.
Learn MoreContact Us
Fill out the form and you will hear from us shortly. We work with founders, scientists, and partners shaping the future of medicine.
General Enquiries
info@legendlifescience.com